A fixed-dose combination (FDC) product designed for the comprehensive management of acid-peptic disorders, particularly those complicated by anxiety, visceral hyperalgesia, and significant smooth muscle spasm. It combines a benzodiazepine anxiolytic (Chlordiazepoxide), two anticholinergic/antispasmodic agents (Clidinium & Dicyclomine), and a Proton Pump Inhibitor (Rabeprazole). This combination is intended to address the 'brain-gut axis' dysfunction often seen in functional gastrointestinal disorders like Irritable Bowel Syndrome (IBS) and severe, stress-aggravated gastroduodenal ulcers. It is a potent formulation reserved for specific clinical scenarios where monotherapy or simpler combinations are insufficient.
Adult: One tablet twice daily, 30-60 minutes before meals. Maximum duration: 2-4 weeks. Therapy should be initiated at the lowest effective dose.
Note: Swallow the tablet whole with a glass of water. Do not crush, chew, or split. Should be taken on an empty stomach, at least 30-60 minutes before a meal (for optimal Rabeprazole absorption). Avoid concomitant antacids; if needed, take at least 2 hours apart.
This combination employs a multi-target approach: 1) Rabeprazole provides profound and sustained gastric acid suppression by irreversibly inhibiting the H+/K+ ATPase (proton pump) in gastric parietal cells. 2) Dicyclomine and Clidinium act as antimuscarinic agents, blocking acetylcholine at smooth muscle M3 receptors in the GI tract, reducing motility, secretion, and relieving spasm/pain. Dicyclomine may also have a direct smooth muscle relaxant effect. 3) Chlordiazepoxide acts centrally as a benzodiazepine, potentiating GABA-A receptor-mediated inhibitory neurotransmission, reducing anxiety and the central component of visceral hypersensitivity.
Pregnancy: CONTRANDICATED, especially in first trimester. Chlordiazepoxide is FDA Pregnancy Category D (positive evidence of human fetal risk). Associated with risk of congenital malformations ('floppy infant syndrome'), neonatal withdrawal, and respiratory depression. Rabeprazole is Category B, but combination is not recommended. Use only if potential benefit justifies extreme risk to fetus.
Driving: Patients must NOT drive or operate heavy machinery, especially during initial treatment and dose adjustments. The combination causes significant drowsiness, dizziness, and blurred vision.
| Alcohol, Opioids, Barbiturates, other CNS Depressants | Potentiated CNS depression, respiratory depression, sedation, risk of death. | Major |
| Potent CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increased plasma levels and toxicity of Chlordiazepoxide (sedation, ataxia). | Major |
| CYP2C19 Inducers (Rifampicin, St. John's Wort) | Decreased plasma levels and efficacy of Rabeprazole. | Moderate |
| CYP2C19 Inhibitors (Fluconazole, Fluvoxamine) | Increased plasma levels of Rabeprazole. | Moderate |
| Anticholinergics (Tricyclic Antidepressants, Antipsychotics, Antihistamines) | Additive anticholinergic side effects (dry mouth, urinary retention, constipation, confusion). | Major |
| Digoxin | Anticholinergics may increase bioavailability of digoxin, risk of toxicity. | Moderate |
| Warfarin | Rabeprazole may potentially increase INR (monitor closely). | Moderate |
| Methotrexate | PPIs may increase methotrexate levels (especially high-dose), risk of toxicity. | Major |
| Drugs requiring gastric acid for absorption (e.g., Ketoconazole, Iron salts, Atazanavir) | Rabeprazole reduces absorption, decreasing efficacy. | Major |
| Levodopa | Anticholinergics may impair gastric emptying and absorption of levodopa. | Moderate |